New version of Merck's cancer drug faces possible patent battle, WSJ reports
Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday, citing people familiar with ...
Yahoo Finance3d
Merck & Co., Inc. (MRK)
In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other most undervalued biotech stocks to invest in. Trump’s Tariffs and the Pharma Sector On ...
Merck's (NYSE:MRK) Earnings May Just Be The Starting Point
NYSE:MRK Earnings and Revenue History March 4th 2025 How Do Unusual Items Influence Profit? To properly understand Merck's profit results, we need to consider the US$4.2b expense ...
Fierce Pharma4d
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...